|
1
|
Pietruska M, Pietruski J, Nagy K, Brecx M,
Arweiler NB and Sculean A: Four-year results following treatment of
intrabony periodontal defects with an enamel matrix derivative
alone or combined with a biphasic calcium phosphate. Clin Oral
Investig. 16:1191–1197. 2012.
|
|
2
|
Nakase T, Fujii M, Myoui A, Tamai N,
Hayaishi Y, Ueda T, Hamada M, Kawai H and Yoshikawa H: Use of
hydroxyapatite ceramics for treatment of nonunited osseous defect
after open fracture of lower limbs. Arch Orthop Trauma Surg.
129:1539–1534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Z, Guo Z, Bai H, Li J, Li X, Chen G
and Lu J: Clinical evaluation of β-TCP in the treatment of lacunar
bone defects: a prospective, randomized controlled study. Mater Sci
Eng C Mater Biol Appl. 33:1894–1899. 2013.
|
|
4
|
Lindfors NC, Hyvönen P, Nyyssönen M,
Kirjavainen M, Kankare J, Gullichsen E and Salo J: Bioactive glass
S53P4 as bone graft substitute in treatment of osteomyelitis. Bone.
47:212–218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hannink G, Geutjes PJ, Daamen WF and Buma
P: Evaluation of collagen/heparin coated TCP/HA granules for
long-term delivery of BMP-2. J Mater Sci Mater Med. 24:325–332.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sibiya SJ, Olivier EI and Duneas N: High
yield isolation of BMP-2 from bone and in vivo activity of a
combination of BMP-2/TGF-β1. J Biomed Mater Res A. 101:641–646.
2013.PubMed/NCBI
|
|
7
|
Waselau M, Patrikoski M, Juntunen M, et
al: Effects of bioactive glass S53P4 or beta-tricalcium phosphate
and bone morphogenetic protein-2 and bone morphogenetic protein-7
on osteogenic differentiation of human adipose stem cells. J Tissue
Eng. 3:20417314124677892012. View Article : Google Scholar
|
|
8
|
Uskoković V and Desai TA: Phase
composition control of calcium phosphate nanoparticles for tunable
drug delivery kinetics and treatment of osteomyelitis. II.
Antibacterial and osteoblastic response. J Biomed Mater Res A.
101:1427–1436
|
|
9
|
Xing J, Hou T, Luobu B, Luo F, Chen Q, Li
Z, Jin H and Xu J: Anti-infection tissue engineering construct
treating osteomyelitis in rabbit tibia. Tissue Eng Part A.
19:255–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang T, Wen J, Zhou J, Shao Z and Dong J:
Poly (ɛ-caprolactone) coating delays vancomycin delivery from
porous chitosan/β-tricalcium phosphate composites. J Biomed Mater
Res B Appl Biomater. 100:1803–1811. 2012.
|
|
11
|
Jiang P, Qu F, Lin H, Wu X, Xing R and
Zhang J: Macroporous/mesoporous bioglasses doped with
Ag/TiO2 for dual drug action property and bone repair.
IET Nanobiotechnol. 6:93–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Xie Z, Zhang C, et al: Bioactive
borate glass scaffolds: in vitro and in vivo evaluation for use as
a drug delivery system in the treatment of bone infection. J Mater
Sci Mater Med. 21:575–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bergeron E, Marquis ME, Chrétien I and
Faucheux N: Differentiation of preosteoblasts using a delivery
system with BMPs and bioactive glassmicrospheres. J Mater Sci Mater
Med. 18:255–263. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bosemark P, Isaksson H, McDonald MM and
Little DG: Augmentation of autologous bone graft by a combination
of bone morphogenic protein and bisphosphonate increased both
callus volume and strength. Acta Orthop. 84:106–111.
2013.PubMed/NCBI
|
|
15
|
Draenert ME, Kunzelmann KH, Forriol F,
Hickel R and Draenert K: Primary cancellous bone formation with BMP
and micro-chambered beads: experimental study on sheep. Bone.
52:465–473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jung MR, Shim IK, Chung HJ, et al: Local
BMP-7 release from a PLGA scaffolding-matrix for the repair of
osteochondral defects in rabbits. J Control Release. 162:485–491.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan XX, Deng HX, Yu CZ, et al: Mesoporous
bioactive glasses, synthesis and structural characterization.
Non-Cryst Solids. 351:3209–3217. 2005. View Article : Google Scholar
|
|
18
|
Yan X, Huang X, Yu C, et al: The in-vitro
bioactivity of mesoporous bioactive glasses. Biomaterials.
27:3396–3403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Quan Z, Han X, Ye Z, Chenzhong Y and
Wenjun C: Influence of novel nano-mesoporous bioactive glass on the
regulation of IGF-II gene expression in osteoblasts. Cell Biochem
Biophys. 62:119–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Balamurugan A, Benhayoune H, Kannan S, et
al: Cryo-X-ray analysis - A novel tool to better understand the
physicochemical reactions at the bioglass/biological fluid
interface. Microsc Res Tech. 71:684–688. 2008. View Article : Google Scholar
|
|
21
|
Ginsac N, Chenal JM, Meille S, et al:
Crystallization processes at the surface of polylactic
acid-bioactive glass composites during immersion in simulated body
fluid. J Biomed Mater Res B Appl Biomater. 99:412–419. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nganga S, Zhang D, Moritz N, Vallittu PK
and Hupa L: Multi-layer porous fiber-reinforced composites for
implants: in vitro calcium phosphate formation in the presence of
bioactive glass. Dent Mater. 28:1134–1145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Otsuka M, Fujita H, Nakamura T and Kokubo
T: Effects of ceramic component on cephalexin release from
bioactive bone cement consisting of Bis-GMA/TEGDMA resin and
bioactive glass ceramics. Biomed Mater Eng. 11:11–22. 2001.
|
|
24
|
Chakraborty S, Mitra MK, Chaudhuri MG, Sa
B, Das S and Dey R: Study of the release mechanism of Terminalia
chebula extract from nanoporous silica gel. Appl Biochem
Biotechnol. 168:2043–2056. 2012.PubMed/NCBI
|
|
25
|
Petropoulos JH, Papadokostaki KG and
Sanopoulou M: Higuchi's equation and beyond: overview of the
formulation and application of a generalized model of drug release
from polymeric matrices. Int J Pharm. 437:178–191. 2012.
|
|
26
|
Singh V, Bushetti SS, Raju SA, Ahmad R,
Singh M and Ajmal M: Polymeric ocular hydrogels and ophthalmic
inserts for controlled release of timolol maleate. J Pharm
Bioallied Sci. 3:280–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uludag H, Gao T, Porter TJ, Friess W and
Wozney JM: Delivery systems for BMPs: factors contributing to
protein retention at an application site. J Bone Joint Surg Am.
83-A(Suppl 1 Pt 2): S128–S135. 2001.PubMed/NCBI
|
|
28
|
Valentin-Opran A, Wozney J, Csimma C,
Lilly L and Riedel GE: Clinical evaluation of recombinant human
bone morphogenetic protein-2. Clin Orthop Relat Res. 395:110–120.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giganti MG, Liuni F, Celi M, et al:
Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their
correlation with radiographic and clinical assessment in fragility
fractures and high energy fractures. J Biol Regul Homeost Agents.
26:671–680. 2012.PubMed/NCBI
|
|
30
|
Uskoković V and Desai TA: Phase
composition control of calcium phosphate nanoparticles for tunable
drug delivery kinetics and treatment of osteomyelitis. II.
Antibacterial and osteoblastic response. J Biomed Mater Res A.
101:1427–1436
|
|
31
|
Xing J, Hou T, Luobu B, Luo F, Chen Q, Li
Z, Jin H and Xu J: Anti-infection tissue engineering construct
treating osteomyelitis in rabbit tibia. Tissue Eng Part A.
19:255–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
